A valuation of up to $2 trillion is the number attached to Anthropic's debut on public markets. The share price isn't. Neither is the size of the offering. On Monday the company put its prospectus in front of the Securities and Exchange Commission, and as CNBC's Investing Club noted in its coverage of the week's funding announcements, those blanks will be filled in later. What the document does contain, apparently, is a long list of financial commitments, big enough that observers are guessing at a raise in the tens of billions of dollars, possibly as much as $100 billion.

That is the headline. The question I care about more, and the harder one to answer, is what the Anthropic S-1 says about the company's plans for scientific research.

I'll be plain about the state of play. Early coverage of the filing has dwelt on capital and said little about laboratories. Nobody has yet laid out, in public reporting I'd stand behind, a line-by-line account of how the prospectus describes research ambitions. So this is partly a guide to reading the document and partly an argument that the science story may turn out to be the most revealing one in it.

What an S-1 can't hide

A registration statement is a strange literary form. Lawyers write it, bankers edit it, and most people who read it are hunting for the one sentence that changes a model. Still, it has an honesty a blog post or a keynote lacks, because misstating things in it carries legal liability. A company can say in a launch video that it wants to compress a decade of biology into a few years. In an S-1 it has to say how much it spends on research, what that spending buys, and what could go wrong.

Three parts of the document matter most for a story about science. The business description shows how the company sorts its own activities: products, customers, research programs, and which of those it thinks investors should care about. The risk factors show what management is afraid of, and in an AI lab that usually includes regulatory exposure, dependence on a few chip and cloud suppliers, and the cost of training runs that may not pay back. The financial statements show how much of the cash burn goes to research and development and how much to serving paying customers.

That last split is the one to watch. Pure research is a cost center. Applied science sold to pharmaceutical companies, materials firms or national laboratories is a revenue line. Where the filing draws the border between the two will say a good deal about whether Anthropic thinks of science as a mission, a marketing story, or a product.

Two kinds of science, one balance sheet

Here the analysis has to get careful, because "scientific research" can mean two quite different things at a frontier lab.

The first is science done on the models: interpretability, evaluations, alignment work, studies of how systems behave under stress. Anthropic has built much of its public identity on that work. It is real research, published and argued over, and it also happens to be the company's main answer to critics who say the technology is being rushed.

The second is science done with the models: scientists using Claude to read literature, design experiments, analyze data. Anthropic has pushed in that direction in the past couple of years, with a life-sciences offering aimed at drug developers and lab teams and a program handing out API credits to researchers. Those are the outward-facing efforts I know of. Whatever the filing says about them now, or about anything newer, I can't tell you.

The two sit uneasily on a balance sheet. A public company answers to quarterly numbers, and safety research doesn't show up as revenue. Scientific partnerships might, eventually, but drug discovery runs on timelines measured in years and the payoffs are lumpy. An investor weighing a trillion-dollar-plus valuation will want to know which kind of science is being funded and which is being used as a story.

There is a reasonable skeptical view, and it deserves airtime. Plenty of researchers think the claims about AI accelerating discovery run well ahead of the evidence. Models are good at summarizing papers and drafting code; whether they produce findings that survive replication is far less settled. An S-1 isn't a peer-reviewed paper, but it does force a company to describe its science ambitions in language it can be sued over. A cautious filing on that front is informative. So is an expansive one, and the risk-factor section will show whether the lawyers let the ambition stand unqualified.

My own view, for what it's worth: the most revealing sentences won't be the grand ones. They'll be the dull disclosures about how many customers account for how much revenue, and whether any of them are research institutions. Nobody ever quoted a customer-concentration table on a keynote slide.

The size of the bill

Research of any kind has to be paid for with compute, and the compute bill is why the filing is arriving now.

Anthropic didn't pick this week at random, and neither did anyone else. Meta used the same Monday to announce a financing programme of up to $95 billion. It has three parts: a $22.5 billion sale of Class A common stock at $642.62 a share; a preferred-share issue of $12.5 billion; and a $60 billion tranche of non-voting Class C stock, which the company intends to feed into the market over time and which cannot begin before next year. SpaceX's Elon Musk said his company had closed a $40 billion debt deal to buy graphics processors, with Nvidia hardware the exclusive choice. That makes three of the largest names in the field, all asking for money within a few hours of one another.

CNBC's framing was that the funding window is narrowing. Bulls read the demand as proof the capacity is needed. Bears see a capital misallocation in progress, with AI revenues failing to match the spending. A prospectus can't settle that argument, though this one will at least show how much Anthropic has promised to spend, and to whom.

Who gets squeezed first

The pressure is already visible lower down the chain. CoreWeave, the best-known of the smaller cloud providers that rent out GPUs, has fallen about 60 percent from its May 6 high of nearly $139. On Monday it touched a 52-week low just above $51 before recovering slightly with the wider market.

Musk offered a blunt diagnosis. In his post on X, he said debt markets had nearly closed to any company without large revenue beyond AI data centers, and predicted "guppy-level death and consolidation" among the 200-plus so-called neoclouds. He is hardly a neutral voice, since he's buying capacity rather than selling it, but the stock chart doesn't contradict him.

For a research-minded reader the relevant point is who survives. CNBC's argument is that companies with other profitable businesses, namely Meta's advertising, Microsoft's enterprise software, Amazon's retail and Alphabet's ads, can fund AI work out of cash flow. A standalone lab like Anthropic can't. It has to sell either stock or promises, and an IPO is the largest version of that sale. That leaves science in an awkward spot, since long-horizon research is precisely the spending a cash-hungry company is tempted to trim when markets turn.

What to watch

The price range will come first, and it will dominate the news. Look past it. Check whether the use-of-proceeds language mentions research capacity at all, or whether the money is described almost entirely as compute and infrastructure. Then see whether science customers appear by category in the revenue discussion.

A public listing also sharpens a governance question. Once shareholders own the company, any decision to fund open-ended research that doesn't pay back will have to be defended on earnings calls. Whether Anthropic's structure gives it more room than most to do that is something the filing should answer, and something its investors will test within a few quarters of trading.

If the market turns harder before the shares price, the research budget is where the pressure will show up first. That, more than any valuation figure, is what the document is worth reading for.